Meeting
2012 ASCO Annual Meeting
Phase I/randomized phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM): Final results of phase I study.
Authors
Nadia N. Laack
Mayo Clinic, Rochester, MN
Nadia N. Laack , Evanthia Galanis , Clinton Leinweber , Jan C. Buckner , Caterina Giannini , Francois J. Geoffroy , Kurt A. Jaeckle , Jann Nagina Sarkaria
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00869401
Citation
J Clin Oncol 30, 2012 (suppl; abstr 2032)
DOI
10.1200/jco.2012.30.15_suppl.2032
Abstract #
2032
Poster Bd #
20
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A phase I study of chemo-radiotherapy with plerixafor for newly diagnosed glioblastoma (GB).
First Author: Reena Parada Thomas
Poster
2015 ASCO Annual Meeting
Randomized, placebo-controlled, phase II study of dasatinib with standard chemo-radiotherapy for newly diagnosed glioblastoma (GBM), NCCTG N0877 (Alliance).
First Author: Nadia N. Laack
Poster
2018 ASCO Annual Meeting
NRG BN002: Phase I study of checkpoint inhibitors anti-CTLA-4, anti-PD-1, the combination in patients with newly diagnosed glioblastoma.
First Author: Andrew E. Sloan
Poster
2013 ASCO Annual Meeting
Phase I adult brain tumor consortium (ABTC) trial of ABT-888 (veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK) data.
First Author: Lawrence Kleinberg